Skip to main
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 37%
Hold 26%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences has demonstrated a robust performance in the transcatheter aortic valve replacement (TAVR) market, with a 10.6% year-over-year revenue growth, comfortably surpassing consensus estimates. The company’s transcatheter mitral and tricuspid technologies (TMTT) have shown exceptional growth, with a 48.3% increase in sales, reflecting strong adoption rates of their innovative products. Management's increased confidence in achieving its 2026 sales guidance of 8-10% year-over-year growth underlines the company's solid market position and growth potential in the expanding global market for structural heart devices.

Bears say

Edwards Lifesciences's financial outlook appears negative due to a significant miss in adjusted operating margin, attributed primarily to increased selling, general, and administrative expenses that exceeded expectations. Despite reporting strong sales in certain segments such as transcatheter aortic valves, the overall organic growth was underwhelming, leading to earnings per share that fell short of consensus estimates. Furthermore, the company faces numerous risks, including potential market share loss due to emerging competition, slower-than-anticipated growth in key markets, and challenges related to product adoption and clinical trial outcomes, which could hinder its long-term growth trajectory.

Edwards Lifesciences (EW) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 37% recommend Buy, 26% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 19 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $96.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $96.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.